TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2667265

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (ubiquinone) 3x 33.3 mg per day, orally for four months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 598611

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 41
Study: 31825192

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (5.4 mg/kg)
Number of subjects: 184
Study: 31048112

Group type: EXPERIMENTAL
Intervention: Low use alcohol, marijuana, and tobacco users (n = 244)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Hazardous alcohol, tobacco and marijuana users (n = 74)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: High-risk polysubstance users (n = 25)
Number of subjects: 343
Study: 28925969

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg of body mass)
Number of subjects: 20
Study: 24879357

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4837

Group type: EXPERIMENTAL
Intervention: ALA (2 g/day)
Number of subjects: 4837

Group type: EXPERIMENTAL
Intervention: EPA-DHA (400 mg/day)
Number of subjects: 4837

Group type: EXPERIMENTAL
Intervention: EPA-DHA plus ALA
Number of subjects: 4837
Study: 24280596

Group type: EXPERIMENTAL
Intervention: Statin plus ezetimibe 10 mg daily
Number of subjects: 286

Group type: COMPARATOR
Intervention: Statin uptitration (double doses of statin)
Number of subjects: 286
Study: 21989792

Group type: EXPERIMENTAL
Intervention: varespladib methyl 500 mg daily
Number of subjects: 624

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study: 19445545

Group type: EXPERIMENTAL
Intervention: Multimodal treatment (psychopharmacologic treatment combined with psychosocial interventions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychopharmacology alone
Number of subjects: 0
Study: 16803808

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) counseling
Number of subjects: 240

Group type: COMPARATOR
Intervention: Traditional health education (control)
Number of subjects: 240
Study: 14506491

Group type: EXPERIMENTAL
Intervention: Diet containing 35% soy protein and 30% vegetable protein
Number of subjects: 14

Group type: COMPARATOR
Intervention: Usual nephropathy diet (0.8 g/kg protein, 70% animal and 30% vegetable protein)
Number of subjects: 14
Study: 10981570

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (160 microg in 4 ml normal saline)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intrathecal nalbuphine (400 microg in 4 ml normal saline)
Number of subjects: 24
Study: 9277384

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8310144

Group type: EXPERIMENTAL
Intervention: Beams‐Eye‐View designed customised blocks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard radiotherapy technique (implied control)
Number of subjects: 0
Study: 3709028

Group type: EXPERIMENTAL
Intervention: 5 mg oral and intravenous doses of bumetanide (CRF group)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 5 mg oral and intravenous doses of bumetanide (HS group)
Number of subjects: 10
Study: 30092782

Group type: EXPERIMENTAL
Intervention: Sodium excretion
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Potassium excretion
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Sodium-to-potassium ratio
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Associations with potassium intake and sodium-to-potassium ratio
Number of subjects: 364
Study: 26874868

Group type: EXPERIMENTAL
Intervention: Intravaginal practices (IVPs)
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Reporting any sexually transmitted infection in the previous 6 months
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Three or more pregnancies
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Clients who became violent when proposing condom use
Number of subjects: 529
Study: 24336090

Group type: EXPERIMENTAL
Intervention: Teacher-led daily 10-minute stress management intervention for 4 months
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control class (reading from a children's book for 10 minutes daily)
Number of subjects: 14
Study: 22484082

Group type: EXPERIMENTAL
Intervention: RT+P training
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: EMS+P training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Comparison of RT+P and EMS+P
Number of subjects: 16
Study: 20032491

Group type: EXPERIMENTAL
Intervention: Fatty fish (salmon)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Lean fish (cod)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Dietary advice (DA)
Number of subjects: 161
Study: 17658091

Group type: EXPERIMENTAL
Intervention: BMI as a continuous variable
Number of subjects: 1814

Group type: EXPERIMENTAL
Intervention: Palpable tumors
Number of subjects: 1814

Group type: EXPERIMENTAL
Intervention: BMI classified as categorical variable
Number of subjects: 1814

Group type: EXPERIMENTAL
Intervention: Increased BMI
Number of subjects: 1814

Group type: EXPERIMENTAL
Intervention: Obese patients
Number of subjects: 1814
Study: 16055643

Group type: EXPERIMENTAL
Intervention: Internal Motivation to Respond Without Sexism (IMS‐S)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: External Motivation to Respond Without Sexism (EMS‐S)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low Internal and External Motivation to Respond Without Sexism
Number of subjects: 0
Study: 12145020

Group type: EXPERIMENTAL
Intervention: Lactose-containing formula
Number of subjects: 18

Group type: COMPARATOR
Intervention: Lactose-free formula
Number of subjects: 18
Study: 9932590

Group type: EXPERIMENTAL
Intervention: Nostril dilator
Number of subjects: 42
Study: 8578810

Group type: EXPERIMENTAL
Intervention: Universal vaccination of infants in their first year of life and adolescents at 12 years of age in Afragola
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective vaccination of high risk groups in Frattamaggiore
Number of subjects: 0
Study: 2093126

Group type: EXPERIMENTAL
Intervention: Propranolol (10 mg) with Quinidine (100 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Propranolol (20 mg) with Quinidine (200 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Propranolol alone (group A)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Propranolol with Quinidine (group A)
Number of subjects: 16
Study: 29719179

Group type: EXPERIMENTAL
Intervention: Verubecestat 12 mg per day
Number of subjects: 1958

Group type: EXPERIMENTAL
Intervention: Verubecestat 40 mg per day
Number of subjects: 1958

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1958
Study: 28947445

Group type: EXPERIMENTAL
Intervention: Bioengineered corneal graft (n=10)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Amniotic membrane (n=5)
Number of subjects: 15
Study: 25844493

Group type: EXPERIMENTAL
Intervention: Early Risers (ER) program
Number of subjects: 270
Study: 23481512

Group type: EXPERIMENTAL
Intervention: mEOC+P
Number of subjects: 200

Group type: COMPARATOR
Intervention: EOC
Number of subjects: 200
Study: 21680059

Group type: EXPERIMENTAL
Intervention: High-flow oxygen (100% oxygen at 15 L/minute by nonrebreather mask for 5 minutes before and during sedation)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Compressed air (15 L/minute by nonrebreather mask for 5 minutes before and during sedation)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: High-flow oxygen
Number of subjects: 117

Group type: COMPARATOR
Intervention: Compressed air
Number of subjects: 117
Study: 19151051

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cuffed tracheal tube
Number of subjects: 25
Study: 16464787

Group type: EXPERIMENTAL
Intervention: Furosemide (80 mg)
Number of subjects: 12
Study: 15210639

Group type: EXPERIMENTAL
Intervention: Video featuring a low SES patient
Number of subjects: 205

Group type: COMPARATOR
Intervention: Video featuring a high SES patient
Number of subjects: 205
Study: 11280530

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 2425

Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily
Number of subjects: 2425

Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 2425

Group type: COMPARATOR
Intervention: Esomeprazole and Omeprazole
Number of subjects: 2425
Study: 9815675

Group type: EXPERIMENTAL
Intervention: Central lymphatic irradiation (CLI)
Number of subjects: 20
Study: 8508864

Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 18
Study: 3429691

Group type: EXPERIMENTAL
Intervention: Patient-initiated postmarketing surveillance system
Number of subjects: 2705

Group type: COMPARATOR
Intervention: Control group (no self-monitoring request)
Number of subjects: 2705
Study: 30513030

Group type: EXPERIMENTAL
Intervention: Nasal high-frequency oscillation ventilation (NHFOV)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 124
Study: 30830114

Group type: EXPERIMENTAL
Intervention: GPIIIa gene polymorphism (T1565C, rs5918) in Erzya with ischemic stroke
Number of subjects: 248

Group type: COMPARATOR
Intervention: GPIIIa gene polymorphism (T1565C, rs5918) in healthy Erzya
Number of subjects: 248

Group type: COMPARATOR
Intervention: eNOS gene polymorphism (G894T, rs1799983) in healthy Erzya
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: eNOS gene polymorphism (G894T, rs1799983) in Russian patients with stroke
Number of subjects: 248
Study: 27391639

Group type: EXPERIMENTAL
Intervention: 5% Minoxidil Foam (MTF)
Number of subjects: 404
Study: 24622243

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: sST2 <33.2 ng/mL
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: Increases in sST2 for 12 months
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: Baseline sST2
Number of subjects: 1650
Study: 24032185

Group type: EXPERIMENTAL
Intervention: Spinal balancing combined with intervention of pathway of qi
Number of subjects: 274

Group type: COMPARATOR
Intervention: Conventional acupuncture and massage therapy
Number of subjects: 274
Study: 20635100

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 120
Study: 18835318

Group type: EXPERIMENTAL
Intervention: 2-dose recombinant vaccine
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: 3-dose recombinant vaccine
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: 3-dose plasma-derived vaccine
Number of subjects: 318
Study: 16983187

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 25
Study: 15297847

Group type: EXPERIMENTAL
Intervention: Thalidomide plus oral melphalan (TM group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Thalidomide alone (T group)
Number of subjects: 50
Study: 11789969

Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg bid
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Cilostazol 50 mg bid
Number of subjects: 910

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 910
Study: 9044010

Group type: EXPERIMENTAL
Intervention: Nurse-led clinic
Number of subjects: 70

Group type: COMPARATOR
Intervention: Rheumatologist's clinic
Number of subjects: 70
Study: 8345035

Group type: EXPERIMENTAL
Intervention: CGS 20267 (0.1 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CGS 20267 (0.5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CGS 20267 (2.5 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3678063

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist consultation in clinic A
Number of subjects: 512

Group type: COMPARATOR
Intervention: Control group clinic B
Number of subjects: 512

Group type: COMPARATOR
Intervention: Control group clinic C
Number of subjects: 512
Study: 31027435

Group type: EXPERIMENTAL
Intervention: AMPH EROS 18.8 mg under fed conditions
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AMPH EROS 18.8 mg under fasted conditions
Number of subjects: 30

Group type: COMPARATOR
Intervention: IR MAS 30 mg under fasted conditions
Number of subjects: 30
Study: 30824246

Group type: EXPERIMENTAL
Intervention: High homework adherence
Number of subjects: 311

Group type: COMPARATOR
Intervention: Low homework adherence
Number of subjects: 311
Study: 29903095

Group type: EXPERIMENTAL
Intervention: VD supplementation group (800 IU/d for 4 weeks)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Outdoor time intervention group (more than 30 min/d for 4 weeks)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 170
Study: 25250647

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg intravenous, administered 1 hr before and 2 hr after cerebral angiography.
Number of subjects: 160

Group type: COMPARATOR
Intervention: No NAC (control group).
Number of subjects: 160
Study: 23348843

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 32
Study: 22097196

Group type: COMPARATOR
Intervention: Enteral Nutrition (EN)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Modified Bazhen Decoction (BZD) in assistant with EN
Number of subjects: 88

Group type: COMPARATOR
Intervention: Parenteral Nutrition
Number of subjects: 88
Study: 19165664

Group type: EXPERIMENTAL
Intervention: recombinant hCG (Ovitrelle 250 microgr, n = 106)
Number of subjects: 257

Group type: COMPARATOR
Intervention: GnRH agonist (triptorelin 0.2 mg, n = 106)
Number of subjects: 257
Study: 16621849

Group type: EXPERIMENTAL
Intervention: Training plus a forearm support
Number of subjects: 182

Group type: COMPARATOR
Intervention: Training only
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Training plus a trackball
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Training plus a forearm support and trackball
Number of subjects: 182
Study: 14762743

Group type: EXPERIMENTAL
Intervention: Surgical reduction and rigid fixation (n = 37)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Closed treatment without surgical reduction (n = 44)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 81
Study: 11846325

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 1704
Study: 9646621

Group type: EXPERIMENTAL
Intervention: 5 mg atorvastatin
Number of subjects: 78

Group type: COMPARATOR
Intervention: 10 mg simvastatin
Number of subjects: 78

Group type: COMPARATOR
Intervention: 20 mg pravastatin
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 20 mg atorvastatin
Number of subjects: 78
Study: 8195651

Group type: EXPERIMENTAL
Intervention: Betaseron
Number of subjects: 0
Study: 2884706

Group type: EXPERIMENTAL
Intervention: Broxaterol 0.5 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Salbutamol 4.0 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 29618476

Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing (ATP)
Number of subjects: 924
Study: 26793956

Group type: EXPERIMENTAL
Intervention: Continued thienopyridine plus aspirin
Number of subjects: 4703
Study: 25210447

Group type: EXPERIMENTAL
Intervention: Structured physical activity program
Number of subjects: 0
Study: 21899803

Group type: EXPERIMENTAL
Intervention: Richly fortified complementary/replacement food
Number of subjects: 743

Group type: COMPARATOR
Intervention: Basal-fortified complementary/replacement food
Number of subjects: 743
Study: 20886790

Group type: EXPERIMENTAL
Intervention: Scalp point penetration needling (observation group)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Routine acupuncture (control group)
Number of subjects: 66
Study: 18718423

Group type: EXPERIMENTAL
Intervention: Circulating soluble angiotensin-converting enzyme 2 (sACE2) activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: sACE2 activity
Number of subjects: 0
Study: 16450594

Group type: EXPERIMENTAL
Intervention: Prophylactic intravenous lidocaine 1 mg/kg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Therapeutic intravenous lidocaine 0.5 mg/kg
Number of subjects: 200
Study: 12801256

Group type: EXPERIMENTAL
Intervention: Whole abdominal radiotherapy
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 172

Group type: COMPARATOR
Intervention: No further treatment (control)
Number of subjects: 172
Study: 10569330

Group type: EXPERIMENTAL
Intervention: HPMC 2.5 g/day
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: HPMC 5.0 g/day
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: HPMC 7.5 g/day
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 8903534

Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 33

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 33
Study: 1812425

Group type: EXPERIMENTAL
Intervention: Outer membrane vesicle vaccine
Number of subjects: 171800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171800

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 171800
Study: 6313522

Group type: COMPARATOR
Intervention: twice-daily placebo (n = 77)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: twice-daily captopril 25 mg (n = 77)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: twice-daily captopril 50 mg (n = 71)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: twice-daily captopril 100 mg (n = 69)
Number of subjects: 294
Study: 30924570

Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet (LCD < 100 g carbohydrate/d)
Number of subjects: 14

Group type: COMPARATOR
Intervention: High carbohydrate diet (HCD > 250 g carbohydrate/d)
Number of subjects: 14
Study: 30217492

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 850

Group type: COMPARATOR
Intervention: Nonprotocol therapy
Number of subjects: 850

Group type: COMPARATOR
Intervention: No further therapy
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Atezolizumab TBP
Number of subjects: 850
Study: 27535063

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COCs) containing 30μg ethinylestradiol (EE) and 3mg drospirenone (DRSP) in a 21/7 regimen
Number of subjects: 80

Group type: COMPARATOR
Intervention: Barrier contraceptive method (BCM) or natural family planning method (NFPM)
Number of subjects: 80
Study: 24614750

Group type: EXPERIMENTAL
Intervention: High-performance water filters and improved stoves
Number of subjects: 566
Study: 22963592

Group type: EXPERIMENTAL
Intervention: Nonblind clinician and patient ratings of treatment response
Number of subjects: 71

Group type: COMPARATOR
Intervention: Independent evaluators (IEs) ratings using Clinician's Global Impressions‐Improvement Scale (CGI‐I)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Therapists' ratings
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Growth curve models
Number of subjects: 71
Study: 21526664

Group type: EXPERIMENTAL
Intervention: Fentanyl pretreatment (1 microg/kg diluted in saline to a volume of 5 ml)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (5 ml normal saline)
Number of subjects: 200
Study: 17693179

Group type: EXPERIMENTAL
Intervention: Sapropterin (10 mg/kg, oral, once daily for 6 weeks)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo (oral, once daily for 6 weeks)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Sapropterin
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 15599357

Group type: EXPERIMENTAL
Intervention: Pulp Canal Sealer EWT
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sealapex
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: AH Plus
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control groups (not specified)
Number of subjects: 80
Study: 12907484

Group type: EXPERIMENTAL
Intervention: Higher sun exposure when aged 6-15 years (average 2-3 hours or more a day in summer during weekends and holidays)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Higher exposure in winter
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Greater actinic damage (grades 4-6 disease)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Decreasing sun exposure when aged 6-15 years
Number of subjects: 408
Study: 10323379

Group type: EXPERIMENTAL
Intervention: High dose GH treatment (66 or 100 microg/kg x day s.c. over 2 years)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Second course of GH treatment (66 microg/kg x day s.c.)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: No further GH treatment after initial GH withdrawal (mean adjusted height SD score -2.7, n = 13)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: No further GH treatment after initial GH withdrawal (mean adjusted height -3.3 SD score, n = 9)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 38
Study: 8532469

Group type: EXPERIMENTAL
Intervention: One of four randomly assigned intervention strategies
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study: 1752175

Group type: EXPERIMENTAL
Intervention: Maprotiline (home made)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Ludimil (Cida‐Geigy)
Number of subjects: 96
Study: 6120705

Group type: EXPERIMENTAL
Intervention: 15 mg of midazolam (Ro 21‐3981, Dormicum) administered p.o.
Number of subjects: 40

Group type: COMPARATOR
Intervention: 7 mg of oxazepam administered p.o.
Number of subjects: 40
Study: 30643079

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg dual therapy
Number of subjects: 240

Group type: COMPARATOR
Intervention: Warfarin triple therapy
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg dual therapy
Number of subjects: 240
Study: 28257326

Group type: EXPERIMENTAL
Intervention: Radioactive Seed Localization (RSL)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Wire-guided Localization (WGL)
Number of subjects: 409
Study: 26022669

Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo)
Number of subjects: 0
Study: 25042290

Group type: COMPARATOR
Intervention: US $2.50 food voucher (200 Kenya shillings)
Number of subjects: 1504

Group type: EXPERIMENTAL
Intervention: US $8.75 food voucher (700 Kenya shillings)
Number of subjects: 1504

Group type: EXPERIMENTAL
Intervention: US $15.00 food voucher (1200 Kenya shillings)
Number of subjects: 1504

Group type: COMPARATOR
Intervention: Control group (no compensation)
Number of subjects: 1504